跳到正文
原文
STAT Pharma 医药频道· Meghana Keshavan·· 22 天前AI 评分57

HHS 允许持证药房与医生临时配制六种实验性肽类,FDA 科学家提出异议

STAT+: HHS green lights six peptides, despite concerns from FDA scientists

AI 导读

HHS 发布政策,允许持证药房和医生临时配制六种实验性肽类,其中包括 BPC-157 和 TB-500,联邦层面暂不对此执法。FDA 职业科学家对此表示反对,认为目前缺乏证据表明这些物质安全或有效。报道由 STAT 的 Margaret Manto 撰写,称此举是对当前肽类热潮的监管助推。

正文

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

I have a cold again. Cure it, science.

HHS opens peptide floodgates, despite concerns from FDA scientists

The Trump administration is giving the peptide craze a regulatory boost. HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including the popular injury-recovery duo BPC-157 and TB-500, without fear of federal enforcement, STAT’s Margaret Manto writes. This comes despite objections from FDA career scientists who say there’s scant evidence the substances are safe or effective.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com